ES2380812T3 - Polipéptidos homólogos a IL-17 y usos terapéuticos de los mismos - Google Patents

Polipéptidos homólogos a IL-17 y usos terapéuticos de los mismos Download PDF

Info

Publication number
ES2380812T3
ES2380812T3 ES07016903T ES07016903T ES2380812T3 ES 2380812 T3 ES2380812 T3 ES 2380812T3 ES 07016903 T ES07016903 T ES 07016903T ES 07016903 T ES07016903 T ES 07016903T ES 2380812 T3 ES2380812 T3 ES 2380812T3
Authority
ES
Spain
Prior art keywords
polypeptide
antibody
pro
nucleic acid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES07016903T
Other languages
English (en)
Spanish (es)
Inventor
Jian Chen
Ellen; Fong Sherman Filvaroff
Audrey; Godowski Paul J. Goddard
Christopher J.; Gurney Austin L. Grimaldi
Hanzhong; Hillan Kenneth J. Li
Daniel; van Lockeren Menno Tumas
Richard L.; Watanabe Colin K. Vandlen
P. Mickey; Wood William I. Williams
Daniel G. Yansura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/031274 external-priority patent/WO2000053752A2/en
Priority claimed from PCT/US2000/004341 external-priority patent/WO2000053756A2/en
Priority claimed from PCT/US2000/005841 external-priority patent/WO2000053758A2/en
Priority claimed from PCT/US2000/007532 external-priority patent/WO2000070050A1/en
Priority claimed from PCT/US2000/015264 external-priority patent/WO2000073452A2/en
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/en
Priority claimed from PCT/US2000/030873 external-priority patent/WO2001040465A2/en
Priority claimed from PCT/US2000/032678 external-priority patent/WO2001040466A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ES2380812T3 publication Critical patent/ES2380812T3/es
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
ES07016903T 1999-12-23 2000-12-20 Polipéptidos homólogos a IL-17 y usos terapéuticos de los mismos Expired - Lifetime ES2380812T3 (es)

Applications Claiming Priority (30)

Application Number Priority Date Filing Date Title
US17209699P 1999-12-23 1999-12-23
US172096P 1999-12-23
PCT/US1999/031274 WO2000053752A2 (en) 1999-03-08 1999-12-30 Promotion or inhibition of angiogenesis and cardiovascularization
WOPCT/US99/31274 1999-12-30
US17548100P 2000-01-11 2000-01-11
US175481P 2000-01-11
WOPCT/US00/04341 2000-02-18
PCT/US2000/004341 WO2000053756A2 (en) 1999-03-08 2000-02-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
WOPCT/US00/05841 2000-03-02
PCT/US2000/005841 WO2000053758A2 (en) 1999-03-08 2000-03-02 Compositions and methods for the treatment of immune related diseases
US19100700P 2000-03-21 2000-03-21
WOPCT/US00/07532 2000-03-21
PCT/US2000/007532 WO2000070050A1 (en) 1999-05-14 2000-03-21 Compositions and methods for the treatment of immune related diseases
US191007P 2000-03-21
WOPCT/US00/15264 2000-06-02
PCT/US2000/015264 WO2000073452A2 (en) 1999-06-02 2000-06-02 Compositions and methods for the treatment of immune related diseases
US21380700P 2000-06-22 2000-06-22
US213807P 2000-06-22
US64484800A 2000-08-22 2000-08-22
US644848 2000-08-22
WOPCT/US00/23328 2000-08-24
PCT/US2000/023328 WO2001016318A2 (en) 1999-09-01 2000-08-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
US24283700P 2000-10-24 2000-10-24
US242837P 2000-10-24
WOPCT/US00/30873 2000-11-10
PCT/US2000/030873 WO2001040465A2 (en) 1999-11-30 2000-11-10 Compositions and methods for the treatment of immune related diseases
US25364600P 2000-11-28 2000-11-28
US253646P 2000-11-28
WOPCT/US00/32678 2000-12-01
PCT/US2000/032678 WO2001040466A2 (en) 1999-12-01 2000-12-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same

Publications (1)

Publication Number Publication Date
ES2380812T3 true ES2380812T3 (es) 2012-05-18

Family

ID=40140243

Family Applications (7)

Application Number Title Priority Date Filing Date
ES07016903T Expired - Lifetime ES2380812T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos a IL-17 y usos terapéuticos de los mismos
ES10009491.1T Expired - Lifetime ES2458349T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos IL-17 y usos terapéuticos de los mismos
ES07016899T Expired - Lifetime ES2379101T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos IL-17 y usos terapéuticos de los mismos
ES09009972.2T Expired - Lifetime ES2506665T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos IL-17 e IL-17R y usos terapéuticos de los mismos
ES00989401T Expired - Lifetime ES2333772T3 (es) 1999-12-23 2000-12-20 Polipeptidos homologos de il-17 y il-17r y sus utilizaciones terapeuticas.
ES07016902T Expired - Lifetime ES2388748T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos a IL-17 y usos terapéuticos de los mismos
ES07016901T Expired - Lifetime ES2380958T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos IL-17 y utilizaciones terapéuticas de los mismos

Family Applications After (6)

Application Number Title Priority Date Filing Date
ES10009491.1T Expired - Lifetime ES2458349T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos IL-17 y usos terapéuticos de los mismos
ES07016899T Expired - Lifetime ES2379101T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos IL-17 y usos terapéuticos de los mismos
ES09009972.2T Expired - Lifetime ES2506665T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos IL-17 e IL-17R y usos terapéuticos de los mismos
ES00989401T Expired - Lifetime ES2333772T3 (es) 1999-12-23 2000-12-20 Polipeptidos homologos de il-17 y il-17r y sus utilizaciones terapeuticas.
ES07016902T Expired - Lifetime ES2388748T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos a IL-17 y usos terapéuticos de los mismos
ES07016901T Expired - Lifetime ES2380958T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos IL-17 y utilizaciones terapéuticas de los mismos

Country Status (10)

Country Link
EP (1) EP1240325B1 (https=)
JP (10) JP5070117B2 (https=)
AT (5) ATE541930T1 (https=)
AU (1) AU2590901A (https=)
CA (1) CA2391374A1 (https=)
CY (1) CY1112334T1 (https=)
DK (1) DK1240325T3 (https=)
ES (7) ES2380812T3 (https=)
PT (4) PT1240325E (https=)
WO (1) WO2001046420A2 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562578B1 (en) 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
AU740405B2 (en) 1998-05-15 2001-11-01 Genentech Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
AU2001241816A1 (en) * 2000-02-29 2001-09-12 Zymogenetics Inc. Methods for promoting production of myelin by schwann cells
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
DE60136921D1 (de) * 2000-04-18 2009-01-22 Schering Corp Medizinische Verwendung von IL-174 Agonisten und Antagonisten
US20030092881A1 (en) * 2000-05-24 2003-05-15 Gorman Daniel M. Mammalian receptor proteins; related reagents and methods
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002008259A2 (en) * 2000-07-26 2002-01-31 Zymogenetics, Inc. Human cytokine receptor
EP1529843A3 (en) * 2000-08-11 2005-06-08 Eli Lilly & Company Novel secreted proteins and their uses
DE60125563T2 (de) * 2000-10-13 2007-10-04 Eli Lilly And Co., Indianapolis Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten
WO2002038764A2 (en) * 2000-11-10 2002-05-16 The Regents Of The University Of California Il-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
WO2003034984A2 (en) * 2001-10-19 2003-05-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
US20060281146A1 (en) * 2002-09-11 2006-12-14 Genetech, Inc. Novel compositions and methods for the treatment of immune related diseases
JP2011516026A (ja) * 2002-11-26 2011-05-26 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
US7749695B2 (en) * 2003-03-03 2010-07-06 Alexander Abbas PRO polypeptides for diagnosis of systemic lupus erythematosis
EP2784084B2 (en) 2003-07-08 2023-10-04 Novartis Pharma AG Antagonist antibodies to IL-17A/F heterologous polypeptides
HUE026260T2 (en) 2003-11-21 2016-06-28 Ucb Biopharma Sprl A method for treating multiple sclerosis by inhibiting IL-17 activity
BRPI0510617A (pt) 2004-05-03 2007-10-30 Schering Corp uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
US7910540B2 (en) 2004-06-10 2011-03-22 Zymogenetics, Inc. Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation
US20080286227A1 (en) * 2004-09-21 2008-11-20 Applied Research Systems Ars Holding N.V. Use of Il-17F for the Treatment and/or Prevention of Neurologic Diseases
CA2616831A1 (en) * 2005-08-04 2007-02-15 Zymogenetics, Inc. Treatment of wounds using il-17b
US20070249533A1 (en) 2005-09-28 2007-10-25 Levin Steven D Il-17a and il-17f antagonists and methods of using the same
WO2008039553A1 (en) 2006-02-10 2008-04-03 Zymogenetics, Inc. Soluble il-17rcx4 and methods of using in inflammation
JP2010507382A (ja) 2006-10-26 2010-03-11 ノヴォ ノルディスク アクティーゼルスカブ Ｉｌ−２１変異体
EP2089050A2 (en) * 2006-11-08 2009-08-19 Zymogenetics, Inc. Il- 17b for use in wound healing
US7790676B2 (en) 2007-03-28 2010-09-07 Zymogenetics, Inc. Soluble IL-17RA/RC fusion proteins
RU2474588C2 (ru) 2008-05-05 2013-02-10 Новиммун Са Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
EP2406282A1 (en) 2009-03-11 2012-01-18 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
MA33248B1 (fr) 2009-04-01 2012-05-02 Genentech Inc Traitement de troubles résistant à l'insuline
GB0905972D0 (en) 2009-04-06 2009-05-20 Medical Res Council Antibodies against IL-17BR
CN102458437B (zh) 2009-05-05 2015-06-10 诺维莫尼公司 抗il-17f抗体及其使用方法
WO2010142551A2 (en) * 2009-06-12 2010-12-16 Ablynx N.V. Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family
WO2012098113A1 (en) 2011-01-17 2012-07-26 Novo Nordisk A/S Il-21 ligands
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
ME03073B (me) 2011-10-19 2019-01-20 Galapagos Nv Ant agonisti il17с za lečenje zapaljenskih poremećaja
JP6236948B2 (ja) * 2013-07-17 2017-11-29 東ソー株式会社 抗体精製用溶出液および当該溶出液を用いた抗体精製方法
KR20150050921A (ko) * 2013-11-01 2015-05-11 현대중공업 주식회사 폐열 회수용 연관식 보일러
WO2016070062A2 (en) 2014-10-31 2016-05-06 Genentech, Inc. Anti-il-17a and il-17f cross reactive antibody variants and compositions comprising and methods of making and using same
JP2018506275A (ja) 2015-01-28 2018-03-08 ジェネンテック， インコーポレイテッド 多発性硬化症の遺伝子発現マーカー及び治療

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073452A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
NZ306653A (en) * 1995-03-23 1999-03-29 Immunex Corp Isolated dna il-17 receptors
WO2000053752A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
KR20010012111A (ko) * 1997-04-25 2001-02-15 리스 데브라 케이. 포유동물의 사이토킨-유사 인자 7
JP2001510035A (ja) * 1997-07-16 2001-07-31 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド インターロイキン−２０
ES2333385T3 (es) * 1997-09-17 2010-02-19 Human Genome Sciences, Inc. Proteina del tipo de interleuquina-17.
US6482923B1 (en) * 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
AU2004799A (en) * 1997-12-19 1999-07-12 Millennium Biotherapeutics, Inc. Novel embryo-derived interleukin related factor molecules and uses therefor
ES2312205T3 (es) * 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
AU740405B2 (en) * 1998-05-15 2001-11-01 Genentech Inc. IL-17 homologous polypeptides and therapeutic uses thereof
WO2000042187A1 (en) * 1999-01-11 2000-07-20 Schering Corporation Interleukin-17 related mammalian cytokine (il-171). polynucleotides encoding them. uses
EP2341144A1 (en) * 1999-01-11 2011-07-06 Schering Corporation Interleukin-17 related mammalian cytokines. Polynucleotides encoding them. Uses
AU3632600A (en) * 1999-05-14 2000-12-05 Genentech Inc. Compositions and methods for the treatment of immune related diseases
EP2241623A3 (en) * 1999-07-07 2010-12-01 ZymoGenetics, Inc. Monoclonal antibody against a human cytokine receptor
JP2003527104A (ja) * 1999-12-23 2003-09-16 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療上の用途

Also Published As

Publication number Publication date
ES2379101T3 (es) 2012-04-20
JP2012152218A (ja) 2012-08-16
HK1114637A1 (en) 2008-11-07
ATE537258T1 (de) 2011-12-15
WO2001046420A8 (en) 2002-07-04
ES2458349T3 (es) 2014-05-05
ATE541931T1 (de) 2012-02-15
ATE541930T1 (de) 2012-02-15
CA2391374A1 (en) 2001-06-28
JP5258691B2 (ja) 2013-08-07
ES2333772T3 (es) 2010-03-01
JP2013165712A (ja) 2013-08-29
WO2001046420A2 (en) 2001-06-28
ES2506665T3 (es) 2014-10-13
ES2388748T3 (es) 2012-10-18
HK1114638A1 (en) 2008-11-07
JP2009159968A (ja) 2009-07-23
JP5070117B2 (ja) 2012-11-07
ATE519847T1 (de) 2011-08-15
HK1114636A1 (en) 2008-11-07
AU2590901A (en) 2001-07-03
JP2015077137A (ja) 2015-04-23
JP2014239685A (ja) 2014-12-25
ATE444361T1 (de) 2009-10-15
JP2012115275A (ja) 2012-06-21
PT1897945E (pt) 2012-03-29
CY1112334T1 (el) 2015-12-09
ES2380958T3 (es) 2012-05-21
PT1897947E (pt) 2012-03-29
HK1114635A1 (en) 2008-11-07
JP2008278887A (ja) 2008-11-20
PT1240325E (pt) 2010-01-07
DK1240325T3 (da) 2010-01-25
EP1240325A2 (en) 2002-09-18
JP2015007091A (ja) 2015-01-15
WO2001046420A3 (en) 2002-05-10
EP1240325B1 (en) 2009-09-30
JP2010266454A (ja) 2010-11-25
HK1114634A1 (en) 2008-11-07
HK1150856A1 (en) 2012-01-13
PT1897944E (pt) 2011-11-28
JP2009278996A (ja) 2009-12-03

Similar Documents

Publication Publication Date Title
ES2380812T3 (es) Polipéptidos homólogos a IL-17 y usos terapéuticos de los mismos
US8034342B2 (en) Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
ES2577532T3 (es) Nueva composición y métodos para el tratamiento de enfermedades relacionadas con el sistema inmune
US7473763B2 (en) Receptor for IL-17 homologous polypeptides and uses thereof
JP2009189367A (ja) Ｉｌ−１７相同的ポリペプチドとその治療上の用途
ES2295224T3 (es) Anticuerpo antagonista anti-pro842.
ES2370423T3 (es) Polipéptidos homólogos il-17 y sus utilizaciones terapéuticas.
ES2317847T3 (es) Composiciones y procedimientos para el tratamiento de enfermedades de tipo inmunologico.
JP2016047051A (ja) Ｉｌ−１７相同的ポリペプチドとその治療上の用途
EP1897943A2 (en) IL-17 homologous polypeptides and therapeutic uses thereof